Bertilimumab

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.

Bertilimumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CCL11 (eotaxin-1)
Clinical data
ATC code	none
Identifiers
CAS Number	375348-49-5 N
ChemSpider	none
NY (what is this?)  (verify)

It was discovered by Cambridge Antibody Technology using their phage display technology.[1] Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.[2]

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3] iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.[4]

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.[5]

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently, iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]

In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) [7] (Herzliya, Israel) in-licensed Bertilimumab from iCo for non-ophthalmic indications.[8] IMMUNE is initiating Phase II clinical trials of Bertilimumab in inflammatory bowel disease (ulcerative colitis & Crohn's disease) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH).